LT3864053T - Rms gydymas, pakeičiant terapiją - Google Patents
Rms gydymas, pakeičiant terapijąInfo
- Publication number
- LT3864053T LT3864053T LTEPPCT/EP2020/075332T LTEP2020075332T LT3864053T LT 3864053 T LT3864053 T LT 3864053T LT EP2020075332 T LTEP2020075332 T LT EP2020075332T LT 3864053 T LT3864053 T LT 3864053T
- Authority
- LT
- Lithuania
- Prior art keywords
- rms
- treatment
- switching therapy
- therapy
- switching
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19196789 | 2019-09-11 | ||
EP20154736 | 2020-01-30 | ||
PCT/EP2020/075332 WO2021048280A1 (en) | 2019-09-11 | 2020-09-10 | Treatment of rms by switching therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3864053T true LT3864053T (lt) | 2023-09-11 |
Family
ID=72709332
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEPPCT/EP2020/075332T LT3864053T (lt) | 2019-09-11 | 2020-09-10 | Rms gydymas, pakeičiant terapiją |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220298253A1 (lt) |
EP (2) | EP3864053B1 (lt) |
JP (1) | JP2022548575A (lt) |
KR (1) | KR20220062025A (lt) |
CN (1) | CN114401742B (lt) |
AU (1) | AU2020344154A1 (lt) |
CA (1) | CA3150947A1 (lt) |
DK (1) | DK3864053T3 (lt) |
ES (1) | ES2957112T3 (lt) |
FI (1) | FI3864053T3 (lt) |
IL (1) | IL290619A (lt) |
LT (1) | LT3864053T (lt) |
MX (1) | MX2022003010A (lt) |
SI (1) | SI3864053T1 (lt) |
WO (1) | WO2021048280A1 (lt) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3216479A1 (en) * | 2021-04-14 | 2022-10-20 | Novartis Ag | Ofatumumab for treating multiple sclerosis in asian patients |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2502552C (en) | 2002-10-17 | 2019-02-12 | Genmab A/S | Human monoclonal antibodies against cd20 |
UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
AR073295A1 (es) * | 2008-09-16 | 2010-10-28 | Genentech Inc | Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion. |
EP2692343A1 (en) * | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
MX2016013944A (es) * | 2014-04-29 | 2017-01-09 | Teva Pharma | Laquinimod para el tratamiento de pacientes con esclerosis multiple recidivante-remitente (rrms) con un alto estado de discapacidad. |
IL302488A (en) | 2016-08-15 | 2023-06-01 | Novartis Ag | Dosing regimens and methods for the treatment of multiple sclerosis using opatumumab |
-
2020
- 2020-09-10 EP EP20785440.7A patent/EP3864053B1/en active Active
- 2020-09-10 WO PCT/EP2020/075332 patent/WO2021048280A1/en active Application Filing
- 2020-09-10 ES ES20785440T patent/ES2957112T3/es active Active
- 2020-09-10 JP JP2022515966A patent/JP2022548575A/ja active Pending
- 2020-09-10 KR KR1020227011366A patent/KR20220062025A/ko unknown
- 2020-09-10 CA CA3150947A patent/CA3150947A1/en active Pending
- 2020-09-10 EP EP23183390.6A patent/EP4230655A3/en active Pending
- 2020-09-10 DK DK20785440.7T patent/DK3864053T3/da active
- 2020-09-10 FI FIEP20785440.7T patent/FI3864053T3/fi active
- 2020-09-10 MX MX2022003010A patent/MX2022003010A/es unknown
- 2020-09-10 AU AU2020344154A patent/AU2020344154A1/en active Pending
- 2020-09-10 CN CN202080064158.9A patent/CN114401742B/zh active Active
- 2020-09-10 LT LTEPPCT/EP2020/075332T patent/LT3864053T/lt unknown
- 2020-09-10 SI SI202030263T patent/SI3864053T1/sl unknown
- 2020-09-10 US US17/753,632 patent/US20220298253A1/en active Pending
-
2022
- 2022-02-14 IL IL290619A patent/IL290619A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020344154A1 (en) | 2022-04-07 |
CN114401742A (zh) | 2022-04-26 |
CN114401742B (zh) | 2024-05-24 |
CA3150947A1 (en) | 2021-03-18 |
EP3864053B1 (en) | 2023-07-05 |
EP3864053A1 (en) | 2021-08-18 |
DK3864053T3 (da) | 2023-09-11 |
KR20220062025A (ko) | 2022-05-13 |
SI3864053T1 (sl) | 2023-12-29 |
WO2021048280A1 (en) | 2021-03-18 |
ES2957112T3 (es) | 2024-01-11 |
IL290619A (en) | 2022-04-01 |
FI3864053T3 (fi) | 2023-09-13 |
US20220298253A1 (en) | 2022-09-22 |
MX2022003010A (es) | 2022-06-02 |
JP2022548575A (ja) | 2022-11-21 |
EP4230655A3 (en) | 2023-11-01 |
EP4230655A2 (en) | 2023-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB201804514D0 (en) | Treatment of pyroptosis | |
IL291362A (en) | Syngap1 brain degeneration treatment | |
EP4096703A4 (en) | THERAPEUTIC USES OF TIRZEPATIDE | |
GB201804515D0 (en) | Treatment of necroptosis | |
IL290619A (en) | rms treatment by switching treatment | |
GB201916428D0 (en) | Treatment of hydro-carbon-contaminated materials | |
PT3864053T (pt) | Tratamento de rms por terapia de mudança | |
GB201907305D0 (en) | Treatment of conditions | |
GB201908076D0 (en) | Skin treatment composition | |
GB201801466D0 (en) | Preparation for treatment of wounds | |
ZA202106250B (en) | Therapeutic uses of dulaglutide | |
IL290983A (en) | Treatment methods | |
GB201918853D0 (en) | Methods of treatment | |
IL289338A (en) | Therapeutic interactions of leucomethylthionine | |
GB201917253D0 (en) | Treatment of conditions | |
GB201900942D0 (en) | Methods of treatment | |
GB201909438D0 (en) | Treatment of diseases | |
EP3979789A4 (en) | TREATMENT OF SAPROLEGNIA | |
GB202113791D0 (en) | Novel therapy | |
GB202107825D0 (en) | Novel therapy | |
AU2019902041A0 (en) | New Therapeutic Treatment Combination | |
GB201904282D0 (en) | Treatment of osteoporotic diseases | |
GB202108302D0 (en) | New treatment | |
GB201904764D0 (en) | Treatment of ophthalmological conditions | |
GB202203017D0 (en) | Novel therapeutic |